NYSE
115.49USD
+0.32 (+0.28%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
285.2B
P/E
—
EPS
—
Beta
0.22
52W range
76.66-125.14
Day range
114.02–115.99
Open
114.86
Prev close
115.17
Volume
6.9M
Avg volume
9.9M
Dividend
3.36
IPO
1978-01-13
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bionxt-engages-business-development-and-licensing-advisors-for-commer-1177137 · 6/15/2026+0.20
https://247wallst.com/investing/2026/06/10/prediction-pfizer-stock-will-double-on-this-date/ · 6/10/2026+0.30
https://www.zacks.com/stock/news/2934794/gilead-merck-report-positive-phase-iii-hiv-study-data-end-nsclc-study?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2934794 · 6/9/2026+0.80
https://www.proactiveinvestors.com/companies/news/1093430/ftse-100-live-index-flat-as-prudential-and-hsbc-fall-us-tech-falls-1093430.html · 6/4/2026+0.75
https://www.prnewswire.com/news-releases/d3-bio-presents-first-line-data-for-elisrasib-d3s-001-at-asco-2026-next-generation-kras-g12c-inhibitor-shows-landmark-efficacy-in-untreated-nsclc-302786434.html · 6/1/2026+0.20
https://www.prnewswire.com/news-releases/the-results-of-phase-iii-optitrop-lung05-study-of-sacituzumab-tirumotecan-sac-tmt-presented-as-an-asco-oral-presentation-and-simultaneously-published-in-the-lancet-302786204.html · 5/30/2026+0.50
https://www.globenewswire.com/news-release/2026/05/29/3303781/32716/en/Gossamer-Bio-Inc-GOSS-Faces-Securities-Class-Action-Amid-80-Drop-On-Phase-3-PROSERA-Trial-Failure-HBSS.html · 5/29/2026+0.20
https://www.prnewswire.com/news-releases/gossamer-bio-inc-goss-faces-securities-class-action-amid-80-drop-on-phase-3-prosera-trial-failure-hbss-302780588.html · 5/23/2026+0.20
https://247wallst.com/investing/2026/05/19/after-reviewing-the-dividend-growth-landscape-schd-just-outperformed-the-sp-500-by-nearly-8-points-and-these-are-the-3-core-funds-that-belong-in-every-long-term-portfolio/ · 5/19/2026+0.40
https://www.prnewswire.com/news-releases/goss-investor-alert-gossamer-bio-investors-with-losses-may-seek-to-lead-the-class-action-after-executives-allegedly-concealed-placebo-risk-hbss-302772627.html · 5/14/2026+0.00
https://www.globenewswire.com/news-release/2026/05/12/3293485/32716/en/GOSS-Investor-Alert-Gossamer-Bio-Investors-With-Losses-May-Seek-to-Lead-the-Class-Action-After-Executives-Allegedly-Concealed-Placebo-Risk-Hagens-Berman.html · 5/12/2026+0.20
https://www.gurufocus.com/news/8846384/merck-faces-gardasil-trial-after-89-billion-sales-peak · 5/8/2026-0.60
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works